Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Pfizer ends phase III trial of inotuzumab ozogamicin

May 21, 2013

Clinical results presented for a novel cancer immunotherapy

May 21, 2013

Northwest Biotherapeutics begins phase III DCVax-L brain cancer trial in Europe

May 17, 2013

OncoMed's anti-Notch 2/3 antibody OMP-59R5 begins study in SCLC

May 16, 2013

FDA accepts supplemental BLA filing for Adcetris

May 15, 2013

MorphoSys begins new phase II trial of MOR-208 in NHL

May 14, 2013

Researchers develop novel vaccine with the potential to block tumor foci formation

May 14, 2013

Novel chimeric antigen receptors presented by HHS

May 13, 2013

Daratumumab receives FDA breakthrough therapy designation

May 3, 2013

MorphoSys begins phase II MOR-208 trial

April 30, 2013

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...